**Thank you for your interest but recruitment for this study is now closed.**
Cancer Survivors and Cannabis Use after its Legalization in Canada
In October 2018, the Canadian government passed the Cannabis Act, which legalized non-medical (i.e., recreational) use of cannabis in Canada. While studies show that the use of cannabis can alleviate some symptoms and side-effects of treatment for those with a cancer diagnosis, little is known about cannabis use amongst cancer survivors.
This study, titled Cancer Survivors’ Preferences for Using Cannabis as a Complementary Therapy after its Legalization in Canada, aims to understand the factors that influence cancer survivors’ decisions to use (or not use) cannabis as a complementary therapy to control or alleviate their cancer symptoms or treatment side effects, and whether medically approved or recreational cannabis is preferred.
We are looking for survivors of cancer to participate in a 1-hour telephone interview about their reasons for using (or not using) cannabis. If you live in Canada, are a survivor of cancer, are 18 years of age or over and are interested in participating in this study, please complete a short eligibility survey by clicking on the link, below. The survey asks for social and demographic information about you and whether you use or have considered using cannabis to help control symptoms and/or lessen the side effects of your cancer treatment. This information is collected by the research team to ensure that a diversity of experiences and perspectives relating to cannabis use by cancer survivors is represented in the study.
You do not need to have used cannabis to participate in this study. The 1-hour telephone interviews will be conducted in English between September and December 2019 and scheduled at a time that is convenient for you.
The study is led by researchers from the Canadian Centre for Applied Research in Cancer Control (ARCC), Simon Fraser University, BC Cancer, and the University of British Columbia. Questions about your information and this survey may be directed to the Principal Investigator or the Interviewer: